About NCDNOR
Article
|Published
The research project NCDNOR aims to elucidate the development of non-communicable diseases (NCD) such as cancer, cardiovascular diseases, diabetes, and lung diseases, and to identify potential underlying causative factors and the significance of various risk factors in the development of these diseases.
Objectives of the project
Norway aims to reduce morbidity and mortality from non-communicable diseases (NCD) such as cancer, cardiovascular diseases, diabetes, and lung diseases. Mental disorders, substance use disorders, and musculoskeletal diseases (specifically hip fractures) are also included as part of the NCD concept. The NCDNOR research project aims to elucidate the development of non-communicable diseases and to identify potential underlying causative factors and the significance of various risk factors in the development of these diseases. This involves describing the significance of various life conditions such as socioeconomic status, family situation, and place of residence. Additionally, it examines how various risk factors such as high blood pressure, tobacco use, overweight/obesity, physical inactivity, and high alcohol consumption affect the risk of developing NCD from a life-course perspective. We also aim to establish better knowledge about how mental health, health behaviors, and biological markers influence disease progression. The research will identify potential areas for structural and more targeted interventions, as well as the possible effects of measures at local and national levels. This will strengthen Norwegian public health efforts in key areas described in the Ministry of Health and Care Services' Public Health Strategy [Folkehelsemeldinga] 2023 (regjeringa.no) (only available in Norwegian).
How we work
The research project is built on broad national collaboration among researchers and various user groups.
The project is an outcome of a broad national collaboration related to the national NCD work to reduce the incidence of premature death from non-communicable diseases by 33 percent by 2030. It is anchored at the Norwegian Institute of Public Health with Inger Ariansen as the project leader. The leadership group includes researchers from the University of Oslo (UiO), the Norwegian University of Science and Technology (NTNU), the Arctic University of Norway (UiT), and representatives from various user groups such as the Norwegian Directorate of Health (Hdir), counties, municipalities, patient associations, and clinical environments.
To create new knowledge in the public health field, we use a compilation of data from national health registers, health surveys, and data managed by Statistics Norway.
The data basis is a compilation of data from national health registers such as the Norwegian Cause of Death Registry, the Cancer Registry of Norway, the Norwegian Prescribed Drug Registry, the Norwegian Control and Payment of Health Reimbursements (KUHR) Database, and the Norwegian Patient Registry. Additionally, we utilize historical hospital data, data from the Trøndelag Health Study (HUNT), the Tromsø Study, nationwide health surveys, and data from registries managed by Statistics Norway. The research group includes researchers from UiO, NTNU, UiT, and the Norwegian Institute of Public Health (including the Cancer Registry of Norway), and possesses high competence in statistics, epidemiological methods, health registers, pharmacology, medicine, and public health.
Key Collatoration Partners
The project's key collaboration partners include the Tromsø Study (UiT), HUNT Research Center (NTNU), the University of Oslo (UiO), the University of Bergen, the Cancer Registry of Norway, the Norwegian School of Sport Sciences (NIH), the counties of Trøndelag and Innlandet, the municipality of Tromsø, the municipality of Levanger, the municipality of Fredrikstad, the Norwegian Health Association, and the Norwegian Directorate of Health.
